Allergan Sues Apotex Over Latisse ANDA

Law360, New York (September 9, 2010, 12:46 PM EDT) -- Allergan Inc. has sued Apotex Inc. in an effort to prevent the Toronto-based drugmaker from introducing a generic version of Latisse, a treatment used to stimulate eyelash growth.

Allergan and Duke University filed a complaint Wednesday in the U.S. District Court for the Middle District of North Carolina, aiming to prevent Apotex and its U.S. unit Apotex Corp. from manufacturing bimatoprost topical solution 0.03 percent.

Apotex notified Allergan in July that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration,...
To view the full article, register now.